Publication Name	World Journal of Gastroenterology
Manuscript ID	109105
Country	United States

Received	2025-04-29 03:00
Peer-Review Started	2025-04-29 03:01
To Make the First Decision
Return for Revision	2025-05-10 01:57
Revised	2025-05-29 15:48
Second Decision	2025-06-30 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-06-30 06:27
Articles in Press	2025-06-30 06:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-07-15 00:26
Publish the Manuscript Online	2025-07-21 09:42

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Gut microbiome-specific nanoparticle-based therapeutics for liver diseases
Manuscript Source	Invited Manuscript
All Author List	Amit Khurana and Phillipp Hartmann
ORCID	Author(s) ORCID Number Phillipp Hartmann http://orcid.org/0000-0003-3658-3335
Funding Agency and Grant Number	Funding Agency Grant Number University of California San Diego Altman Clinical and Translational Research Institute KL2TR001444 2022 Pinnacle Research Award in Liver Diseases from the American Association for the Study of Liver Diseases Foundation PNC22-159963 National Institutes of Health P30 DK120515
Corresponding Author	Phillipp Hartmann, Assistant Professor, MD, Department of Pediatrics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. phhartmann@health.ucsd.edu
Key Words	Nanomedicine; Chronic liver diseases; Gut microbiome; Microbial metabolites; Precision medicine
Core Tip	Chronic liver diseases are driven by metabolic, immune, and microbiome dysregulation. In this review, we detail recent advances in nanomedicine that enable tailored modulation of the gut microbiota, which can improve chronic liver diseases. Nanoparticles increase pharmacological effects and can reduce off-target effects. Further, artificial intelligence and machine learning can aid in production of precision nanomedicine.
Publish Date	2025-07-21 09:42
Citation	<p>Khurana A, Hartmann P. Gut microbiome-specific nanoparticle-based therapeutics for liver diseases. <i>World J Gastroenterol</i> 2025; 31(27): 109105</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i27/109105.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i27.109105

Full Article (PDF)	WJG-31-109105-with-cover.pdf
Manuscript File	109105_Auto_Edited_013622.docx
Answering Reviewers	109105-answering-reviewers.pdf
Audio Core Tip	109105-audio.mp3
Conflict-of-Interest Disclosure Form	109105-conflict-of-interest-statement.pdf
Copyright License Agreement	109105-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	109105-foundation-statement.pdf
Peer-review Report	109105-peer-reviews.pdf
Scientific Misconduct Check	109105-scientific-misconduct-check.png
Scientific Editor Work List	109105-scientific-editor-work-list.pdf
CrossCheck Report	109105-crosscheck-report.pdf